These 4 Stocks Have all the Buzzzz..

February 6, 2025

ON YOUR RADAR

DENVER, Colo., Feb 06, 2025 (247marketnews.com)- 24/7 Market News, a trusted source for real-time financial news and market analysis, highlights today’s most significant stock movements and breaking developments shaping the financial landscape.

(NASDAQ:SYTA) The company is still preparing for its upcoming press conference/ world announcement that will ,”reveal the most significant development in the company’s history,” and Siyata is entering a transformative phase, and this development marks the culmination of months of strategic negotiations and execution. All shareholders are strongly encouraged to attend to appreciate the significant implications for 2025,” stated Marc Seelenfreund, CEO.

Stay tuned for updates on this as it develops.

(NASDAQ:QNTM) The stock continues to surge after the positive clinical tests of it’s unbuzzd product. The stock hit $18 or more dollars today. The company tweeted out this morning, they have hired a leading New York Investment Bank to advise on a capital raise and IPO for this product.

(NASDAQ:LIPO) Lipella Pharmaceuticals just secured FDA approval for an Expanded Access Program (EAP) for LP-310, a breakthrough oral rinse targeting oral lichen planus (OLP), a chronic and painful inflammatory condition affecting 6 million Americans. With no FDA-approved treatments currently available, this milestone positions Lipella at the forefront of addressing a significant unmet medical need. The approval not only validates LP-310’s potential but also accelerates its path to market, offering an early opportunity for patient access while Phase 2a clinical trials progress. As Lipella advances its clinical pipeline, this regulatory win underscores the company’s innovative approach and strengthens its investment potential in the biotech space. The stock is currently up more than 60% on this news during pre-market.

(NASDAQ:RNAZ) TransCode Therapeutics successfully completed initial dosing in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, a first-in-class RNA therapeutic targeting metastatic cancer. With no significant safety or dose-limiting toxicities reported across all three cohorts, the drug continues to show promising pharmacodynamic activity, including a 66% inhibition of miR-10b, a key driver of cancer progression. The dose in Cohort 3 has doubled from the previous cohort, demonstrating a favorable pharmacokinetic profile and potential dose-dependent efficacy. As TransCode advances toward the trial’s dose-expansion phase, these results reinforce confidence in TTX-MC138’s ability to address the unmet need in metastatic cancer treatment, positioning RNAZ as a strong contender in the growing RNA oncology space. The stock hit a high of $14.60 in pre-market on more than usual volume

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SYTA, QNTM, LIPO, RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.